Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

20171,743 citationsJournal Articlebronze Open Access

Authors

Nicholas D. James · University of Birmingham

Johann S. de Bono · Institute of Cancer Research

Melissa Spears · Medical Research Council

Noel W. Clarke · Salford Royal NHS Foundation Trust

Malcolm D. Mason · Cancer Research UK

David P. Dearnaley · University College London

A.W.S. Ritchie

Abstract

Among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher rates of overall and failure-free survival than ADT alone. (Funded by Cancer Research U.K. and others; STAMPEDE ClinicalTrials.gov number, NCT00268476 , and Current Controlled Trials number, ISRCTN78818544 .).

Topics & Keywords

Prostate Cancer Treatment and Research Cancer, Lipids, and Metabolism Hormonal and reproductive studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 377, Issue 4, pp. 338-351

DOI: 10.1056/nejmoa1702900

Field-Weighted Citation Impact: 165.19